A Systematic Review of Complex Polypharmacy in Bipolar Disorder: Prevalence, Clinical Features, Adherence, and Preliminary Recommendations for Practitioners

Instructions

Click the red REGISTER button to pay the $10 fee and take the posttest
Click here to return to the JCP CME article.

Overview

Do you tend to use combination pharmacotherapy regimens in patients with bipolar disorder? Will patients receiving 3 or more drugs have better outcomes?


Read the whole article at psychiatrist.com here:
A Systematic Review of Complex Polypharmacy in Bipolar Disorder: Prevalence, Clinical Features, Adherence, and Preliminary Recommendations for Practitioners

© Copyright 2021 Physicians Postgraduate Press, Inc.

Target Audience

Psychiatrists

Learning Objectives

Regularly weigh risks versus benefits of the components of a complex pharmacotherapy regimen for patients with bipolar disorder

Activity summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Activity opens: 
06/01/2021
Activity expires: 
06/30/2023
Cost:
$10.00
Rating: 
0

CME Background

Articles are selected for credit designation based on an assessment of the educational needs of CME participants, with the purpose of providing readers with a curriculum of CME articles on a variety of topics throughout each volume. Activities are planned using a process that links identified needs with desired results.

CME Objective

After studying this article, you should be able to:

  • Regularly weigh risks versus benefits of the components of a complex pharmacotherapy regimen for patients with bipolar disorder

Statement of Need and Purpose

Treatment of bipolar disorder with multiple medications is a widely used practice, despite risks such as decreasing patients’ adherence and increasing the potential for drug interactions and health concerns. Clinicians need evidence-based recommendations on when this treatment strategy may be used with the greatest potential benefit.

Release, Expiration, and Review Dates

This educational activity was published in June 2021 and is eligible for AMA PRA Category 1 Credit™ through June 31, 2023. The latest review of this material was May 2021.

Disclosure of Off-Label Usage

The authors have determined that, to the best of their knowledge, venlafaxine, mirtazapine, ritanserin, haloperidol, topiramate, and clonazepam are not approved by the US Food and Drug Administration for the treatment of bipolar disorder.

Funding/Support

None.

Faculty Affiliation


Anna M. Kim, MD
Department of Psychiatry, Northwell Health System, New York, New York



Lisa Salstein, MD
Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York



Joseph F. Goldberg, MD*
Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York

 

*Corresponding authors: Joseph F. Goldberg, MD, 128 East Ave, Norwalk, CT 06851 (joseph.goldberg@mssm.edu).

Financial Disclosure

All individuals in a position to influence the content of this activity were asked to complete a statement regarding all relevant personal financial relationships between themselves or their spouse/partner and any commercial interest. The CME Institute has resolved any conflicts of interest that were identified. In the past year, Marlene P. Freeman, MD, Editor in Chief of The Journal of Clinical Psychiatry, has received research funding from JayMac and Sage; has been a member of the advisory boards for Otsuka, Alkermes, and Sunovion; has been a member of the Independent Data Safety and Monitoring Committee for Janssen; has been a member of the Steering Committee for Educational Activities for Medscape; and, as a Massachusetts General Hospital (MGH) employee, works with the MGH National Pregnancy Registry, which is sponsored by Teva, Alkermes, Otsuka, Actavis, and Sunovion, and works with the MGH Clinical Trials Network and Institute, which receives research funding from multiple pharmaceutical companies and the National Institute of Mental Health. No member of the CME Institute staff reported any relevant personal financial relationships.

Dr Goldberg is a consultant to BioXcel, Lundbeck, SAGE Therapeutics, MedScape, Otsuka, Psychiatry and Behavioral Health Learning Network, Sunovion, and WebMD; he serves on the speakers bureaus for Allergan, Intracellular Therapies, Otsuka, and Sunovion; and he receives royalties from American Psychiatric Publishing, Inc, and Cambridge University Press. Drs Kim and Salstein have no personal affiliations or financial relationships with any commercial interest to disclose relative to the article.

Accreditation Statement

The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

The CME Institute of Physicians Postgraduate Press, Inc., designates this journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note: The American Nurses Credentialing Center (ANCC) and the American Academy of Physician Assistants (AAPA) accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Price

Cost:
$10.00
Please login or register to take this activity.

Register for free on our site to participate in this and many free CME courses. There is a $10 processing fee for this activity.